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OBJECTIVES The goal of this study was to determine: 1) whether bradykinin (BK) directly stimulates tissue
plasminogen activator (tPA) secretion in human coronary circulation, and 2) whether
angiotensin-converting enzyme (ACE) inhibition favorably alters the fibrinolytic balance
regulated by BK.
BACKGROUND Bradykinin is a potent stimulator of tPA secretion in endothelial cells; however, the effect of
BK on tPA release in the human coronary circulation has not been studied.
METHODS Fifty-six patients with atypical chest pain were randomly assigned to two groups: 25 patients
were treated with the ACE inhibitor enalapril (ACE inhibitor group), and 31 were not
treated with ACE inhibitors (non-ACE inhibitor group). Graded doses of BK (0.2, 0.6, 2.0
mg/min), acetylcholine (ACh) (30 mg/min) and papaverine (PA) (12 mg) were administered
into the left coronary artery. Coronary blood flow (CBF) was evaluated by Doppler flow
velocity measurement. Blood samples were taken from the aorta (Ao) and the coronary sinus
(CS).
RESULTS Bradykinin induced similar increases in CBF in both groups. The net tPA release induced by
BK was dose-dependently increased in both groups, and the extent of that increase in the
ACE inhibitor group was greater than that in the non-ACE inhibitor group. Bradykinin did
not alter plasminogen activator inhibitor-1 (PAI-1) levels in the Ao or CS in either group.
Neither ACh nor PA altered tPA levels or PAI-1 levels in either group.
CONCLUSIONS Intracoronary infusion of BK stimulates tPA release without causing any change in PAI-1
levels in the human coronary circulation. In addition, this effect of BK is augmented by an
ACE inhibitor. (J Am Coll Cardiol 2001;37:1565–70) © 2001 by the American College of
Cardiology
It is widely accepted that vascular endothelial cells, through
the release of nitric oxide (NO), prostacyclin, tissue-type
plasminogen activator (tPA) and plasminogen activator
inhibitor-1 (PAI-1), play an important role in the regula-
tion of thrombosis and fibrinolysis. Reduced fibrinolytic
activity is associated with an increased risk of myocardial
infarction and cardiovascular mortality (1,2).
Bradykinin (BK) is a vasoactive polypeptide that has
cardioprotective effects (3). There is a growing body of
evidence that BK causes endothelium-dependent vasodila-
tion through the production of NO, prostacyclin and
endothelium-derived hyperpolarizing factor through the B2
receptor in human coronary arteries (4,5). On the other
hand, it has been shown that BK is a potent stimulus for
tPA secretion in cultured endothelial cells (6,7). Brown et
al. (8) demonstrated that infusion of BK results in an
increase in tPA levels throughout the entire body. Recently,
it has been shown that intra-arterial administration of BK
stimulated tPA release in human brachial arteries (9,10).
Nevertheless, the effect of BK on tPA release has not been
examined in the human coronary circulation.
Angiotensin-converting enzyme (ACE) inhibition has
been shown to improve coronary endothelial function
(11,12) and decrease the incidence of ischemic cardiovascu-
lar events in patients with left ventricular dysfunction
(13,14). In patients treated with ACE inhibitors, the
mechanisms that underlie the reduction in coronary throm-
botic events remain unknown. Thus, it is unclear whether
ACE inhibitors favorably alter the fibrinolytic balance by
increasing BK-induced tPA release, decreasing angiotensin
II-mediated PAI-1 release, or both (8,15). Furthermore, the
effects of ACE inhibition on BK-mediated fibrinolytic and
vasomotor responses have not been assessed concurrently in
coronary circulation in the same patients.
In this study, we examined whether BK directly stimu-
lates tPA secretion in human coronary circulation and
whether ACE inhibition favorably alters the fibrinolytic
balance regulated by BK.
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METHODS
Study patients. The eligible subjects for our study were
randomly assigned to two groups: 25 patients were treated
with enalapril (10 mg once daily) (ACE inhibitor group) for
a duration of seven days, and 31 patients were not treated
with an ACE inhibitor (non-ACE inhibitor group). All of
the study patients underwent diagnostic cardiac catheteriza-
tion for the evaluation of atypical chest pain or myocardial
ischemia on electrocardiogram and had angiographically
normal coronary arteries. Secondary hypertension was ex-
cluded based on history, physical examination and appro-
priate laboratory testing (including renal arteriogram, if
indicated). Patients with diabetes mellitus, myocardial in-
farction, congestive heart failure, cardiomyopathy or valvu-
lar heart disease were excluded from the study. All cardiac
medications except for ACE inhibitors were discontinued
for at least 72 h before the study. The ethical committee on
human research of our institution approved the study
protocols, and written informed consent was obtained from
all patients.
Protocol. Cardiac catheterization was performed between
9 AM and 11 AM in the fasting state. A 0.014-inch
Doppler-tipped guidewire (FloWire, Cardiometrics Inc.,
Mountain View, California) was advanced to the proximal
segment of the left anterior descending (LAD) coronary
artery to measure blood flow velocity. All drugs were infused
directly into the left main coronary artery via the guide
catheter at infusion rates ranging between 0.5 and 1 ml/min.
A 6F multipurpose catheter (GCS6, Goodtec, Gifu, Japan)
was inserted via the right femoral vein into the coronary
sinus (CS) for blood sampling. Baseline coronary blood flow
(CBF) velocity, blood sampling and coronary angiography
were performed and confirmed to be unchanged by a 2-min
infusion of saline at 1 ml/min. The following studies were
then performed.
1) Bradykinin was started at 0.2 mg/min and then increased
to 0.6 and 2.0 mg/min for 2 min. During BK infusion,
CBF velocity reached a peak at about 60 s and main-
tained a plateau by 60 s.
2) After completing the protocol with the intracoronary
injection of BK, we waited at least 10 min before
beginning the infusion of acetycholine (ACh) (musca-
rinic receptor-operated endothelium-dependent vasodi-
lator), by which time the coronary diameter and coronary
blood flow velocity had returned to their baseline values.
3) Acetylcholine was given at 30 mg/min for 2 min.
4) Finally, papaverine (endothelium-independent vasodilator)
was given into the left coronary artery at 12 mg for 20 s.
Coronary angiography was performed after each infusion.
Quantitative coronary angiography and measurements of
coronary blood flow. Coronary cineangiograms were re-
corded using a Philips cineangiographic system (Philips
Medical Systems, Tokyo, Japan). The change in diameter of
the LAD coronary artery was measured in a vessel segment
2.5 mm beyond the tip of the Doppler wire. Coronary
angiography was performed using the Judkins technique
with contrast material (Omnipaque, Dai-ichi Pharmaceuti-
cal Co., Tokyo, Japan). Coronary angiograms were analyzed
by QCA using the Cardiovascular Measurement System
(CMS-MEDICS Medical Imaging Systems, Leiden, the
Netherlands). Peak CBF velocity was continuously moni-
tored using a fast Fourier transform-based spectral analyzer
(FloMap, Cardiometrics Inc.). Coronary blood flow was
derived from the CBF velocity and diameter measurements
by the formula: p 3 averaged peak CBF velocity 3 0.125 3
(arterial diameter)2 (16).
Phasic and mean aortic blood pressures, heart rate and
12-lead electrocardiograms were continuously monitored
using a polygraph system (Nihon-Kohden Kogyo Co.,
Tokyo, Japan) and were recorded on a multichannel re-
corder.
Blood sampling and biochemical assays. Paired blood
samples in the aorta (Ao) and CS were taken simultaneously
before the infusion of BK and after the infusion of BK, ACh
and papaverine for the measurement of plasma tPA antigen
and PAI-1 antigen. Blood samples in the Ao and CS were
also obtained at 2 and 4 min after cessation of the infusion
of BK at 2.0 mg/min.
Blood samples were collected on ice and centrifuged
immediately, and plasma was stored at 270°C until the time
of assay. Blood for the measurement of t-PA and PAI-1 was
collected in tubes containing 0.105 mol/L sodium citrate.
Antigen levels were determined using a two-site ELISA
(Biopool, AB, Umea, Sweden) (8).
Arteriovenous concentration gradients were calculated by
subtracting the plasma level measured in simultaneously col-
lected CS venous and arterial blood. Thus, net release or
uptake rates at each time point were calculated as Net Re-
lease 5 (CCS 2 CA) 3 (CBF 3 [{100 2 Hematocrit}/100]).
Statistics. Data are expressed as means 6 SEM. Discrete
variables were expressed as counts or percentages and
compared with the chi-square test. Continuous variables
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ACh 5 acetylcholine
ANOVA 5 analysis of variance
Ao 5 aorta
BK 5 bradykinin
CBF 5 coronary blood flow
CS 5 coronary sinus
LAD 5 left anterior descending
MAP 5 mean arterial pressure
NO 5 nitric oxide
PAI-1 5 plasminogen activator inhibitor-1
PARC 5 plasma active renin concentration
tPA 5 tissue plasminogen activator
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were compared using the unpaired Student t test or a
one-way analysis of variance (ANOVA). When serial
changes in systemic and coronary hemodynamic variables
and fibrinolytic parameters in response to the graded doses
of BK were compared between the two groups, a two-way
ANOVA for repeated measures followed by Bonferroni’s
multiple-comparison test was used. A p value of ,0.05 was
considered statistically significant.
RESULTS
Baseline characteristics. There were no significant differ-
ences in baseline characteristics between the ACE inhibitor
group and the non-ACE inhibitor group, except for mean
arterial pressure (MAP), plasma active renin concentration
(PARC) and ACE. Mean arterial pressure and ACE were
lower in the ACE inhibitor group than in the non-ACE
inhibitor group, while PARC was higher in the ACE
inhibitor group than in the non-ACE inhibitor group
(Table 1).
Systemic and coronary hemodynamics. As illustrated in
Figure 1, intracoronary infusion of BK resulted in a signif-
icant decrease in MAP in the ACE inhibitor group, and this
effect was dose-dependent. However, BK did not alter
MAP in the non-ACE inhibitor group. After the infusion
of each of three graded doses of BK, MAP was significantly
lower in the ACE inhibitor group than it was in the
non-ACE inhibitor group (p , 0.0001). With increasing
doses of BK, heart rate did not change in either group (Fig.
1). The addition of either ACh at 30 mg/min or papaverine
at 12 mg did not cause changes in MAP or heart rate in
either group. Intracoronary infusion of BK increased CBF
in a dose-dependent manner in the two groups, and no
significant differences were observed in the response to BK
between the two groups (Fig. 1). Intracoronary infusion of
papaverine caused an increase in CBF, which was equipo-
tent to that of BK (2.0 mg/min) in both groups. There were
no significant differences in the CBF response to either
ACh or papaverine between the two groups.
Fibrinolytic parameters. Baseline tPA antigen levels at
either the Ao or CS in the ACE inhibitor group (Ao:
6.07 6 0.50, CS: 6.19 6 0.56 ng/ml) were similar to those
in the non-ACE inhibitor group (Ao: 5.93 6 0.56, CS:
5.87 6 0.53 ng/ml).
Table 1. Baseline Characteristics
ACE
(n 5 25)
non-ACE Inhibitor
(n 5 31)
p
Value
Age, yr 61.8 6 2.25 60.3 6 2.0 0.61
Gender, male:female 17:8 23:8 0.83
Smoking, % 13 (52%) 10 (32%) 0.22
Body mass index, kg/m2 24.4 6 0.5 23.0 6 0.6 0.89
Mean arterial pressure, mm Hg 106.4 6 4.2 119.3 6 3.8 0.005
Heart rate, beats/min 65.4 6 2.1 65.3 6 1.9 0.99
Total cholesterol, mg/dl 191.9 6 5.9 193.9 6 5.6 0.80
HDL cholesterol, mg/dl 46.1 6 4.6 44.9 6 2.1 0.78
Triglycerides, mg/dl 126.6 6 11.0 125.3 6 10.8 0.93
PARC, pg/ml 73.5 6 28.3 15.2 6 6.9 0.03
Aldosterone, pg/ml 65.0 6 5.7 70.3 6 6.8 0.56
ACE, IU/l 2.04 6 0.33 9.88 6 0.72 ,0.0001
Epinephrine, pg/ml 69.4 6 9.4 94.9 6 9.7 0.06
Norepinephrine, pg/ml 239.5 6 18.9 299.9 6 36.9 0.13
Mean 6 SE.
ACE 5 angiotensin-converting enzyme; HDL 5 high density lipoproteins; PARC 5 plasma active renin concentration.
Figure 1. The effects of bradykinin (0.2, 0.6, 2.0 mg/min), acetylcholine
(ACh) (30 mg/min) and papaverine (PA) (12 mg) on the mean arterial
pressure (upper panel), heart rate (middle panel) and percent change in
coronary blood flow (lower panel) in the ACE inhibitor group (open box)
and non-ACE inhibitor group (closed circle). *p , 0.05 versus baseline.
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In both the non-ACE inhibitor group and the ACE
inhibitor group, the level of tPA in the Ao was not changed
by the infusion of BK. This level in the ACE inhibitor
group was increased at 2 min after the cessation of BK (Fig.
2, left). In the non-ACE inhibitor group, the level of tPA in
the CS was significantly increased in a dose-dependent
manner by the infusion of graded doses of BK and gradually
declined at 2 min and 4 min after cessation of the infusion
of BK (Fig. 2, right). In the ACE inhibitor group, the level
of tPA in the CS immediately reached a plateau with the
infusion of BK at 0.2 mg/min and remained constant
throughout and for 2 min after cessation of the infusion of
BK (Fig. 2, right). The level of tPA in response to BK in the
CS in the ACE inhibitor group was significantly higher
than that in the non-ACE inhibitor group (p , 0.0001)
(Fig. 2, right), whereas the level of tPA in response to BK
in the Ao was not significantly different between the two
groups (Fig. 2, left). The net tPA release induced by the
intracoronary infusion of BK was increased in both groups,
and the extent of this increase in the ACE inhibitor group
was markedly greater than that in the non-ACE inhibitor
group (p 5 0.0002) (Fig. 3).
Infusion of ACh at a dose of 30 mg/min did not alter the
level of tPA in either the Ao or the CS in either group nor
did infusion of papaverine alter the level of tPA in either the
Ao or the CS in either group. Neither ACh nor papaverine
caused a significant change in net tPA release in either
group.
The basal level of PAI-1 in either the Ao or the CS did
not differ between the two groups. With an increase in BK
dosage, the level of PAI-1 in the CS tended to decrease
compared with that in the Ao in both groups; however,
there were no significant differences in either group. Neither
ACh nor papaverine had any significant effects on the level
of PAI-1 in either the Ao or CS in either group (Fig. 4).
DISCUSSION
This is the first report that demonstrates that intracoronary
infusion of BK caused a significant increase in tPA antigen
levels, and ACE inhibitors augmented this stimulatory
effect of BK in the human coronary circulation.
Systemic and coronary hemodynamic changes. In the
ACE inhibitor group, MAP was significantly decreased in a
dose-dependent fashion, whereas this effect was not ob-
served in the non-ACE inhibitor group. These results were
consistent with previous studies in which BK was given at
doses of up to 10 mg/kg/min (8). Bradykinin relaxes human
coronary arteries through the stimulation of endothelial B2
receptors, leading to the production of NO, prostacyclin and
endothelium-derived hyperpolarizing factor (4,5).
Angiotensin-converting enzyme inhibitors may act on kini-
nase II and increase the tissue concentrations of BK, which
would augment the vasodilation induced by BK. Previous
studies have shown that intracoronary infusion of BK
increased coronary artery diameter and CBF, and these
effects were augmented by acute intravenous administration
of enalaprilat in human subjects (17). In this study, the
increases in CBF induced by BK at 2.0 mg/min in the ACE
inhibitor group were comparable with those in the non-
ACE inhibitor group. Therefore, our results suggest that
the effects of ACE inhibitors on fibrinolytic changes in
response to BK were not associated with coronary hemody-
namic changes.
Figure 3. The effects of bradykinin (0.2, 0.6, 2.0 mg/min), acetylcholine
(ACh) (30 mg/min) and papaverine (PA) (12 mg) on net tissue plasmin-
ogen activator (tPA) release in the angiotensin-converting enzyme inhib-
itor group (open box) and the nonangiotensin-converting enzyme inhibitor
group (closed circle). *p , 0.05 versus baseline.
Figure 2. The effects of bradykinin (0.2, 0.6, 2.0 mg/min), acetylcholine (ACh) (30 mg/min) and papaverine (PA) (12 mg) on tissue plasminogen activator
(tPA) antigen in the aorta (Ao) and coronary sinus (CS) in the angiotensin-converting enzyme inhibitor group (open box) and the nonangiotensin-
converting enzyme inhibitor group (closed circle). 2 min: 2 min after cessation of the infusion of bradykinin; 4 min: 4 min after cessation of the infusion
of bradykinin. *p , 0.05 versus baseline.
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tPA. Tissue plasminogen activator, the key factor in the
initiation of fibrinolysis, is synthesized in endothelial cells,
stored in small, dense vesicles and secreted by endothelial
cells in response to several vasoactive agents (18).
In both groups, the net tPA antigen release induced by
BK was increased, suggesting that tPA antigen is released
during transcardiac passage. The extent of that increase in
the ACE inhibitor group was markedly greater than that in
the non-ACE inhibitor group. Therefore, the present data
may provide insight into the mechanisms through which
ACE inhibitors reduce the risk of ischemic cardiovascular
events in clinical trials (13,14). On the basis of our data,
ACE inhibitors may not only improve coronary endothelial
vasomotor function (11,12), but may also have favorable
effects on the coronary fibrinolytic balance through poten-
tiation of the effects of BK in humans, resulting in a
decrease in ischemic cardiovascular events.
Brown et al. (8) reported that systemic administration of
BK caused an increase in venous tPA antigen concentrations
in captopril- or quinapril-pretreated subjects. Subsequently,
they demonstrated that BK stimulates tPA release in human
brachial arteries. However, few previous studies have exam-
ined the mechanisms underlying the stimulation of tPA
release induced by BK in humans.
Intracoronary infusion of ACh did not change the plasma
level of tPA antigen in either the Ao or CS. The effects of
tPA release induced by ACh in the human vasculature are
controversial (9,19). One possible explanation is that the
stimulation of endothelial muscarinic receptors induced by
methacholine may cause local tPA production in human
forearm circulation since ACh and methacholine differ with
regard to their potency for stimulating tPA release. In this
study, the increase in CBF induced by ACh at a concen-
tration of 30 mg/min was significantly less than that induced
by BK, but a further increase in the dose of ACh (up to
100 mg/min) directly contracts human coronary vascular
smooth muscle cells apart from endothelium (data not
shown). Therefore, as far as human coronary arteries are
concerned, it is likely that the dose of ACh administered or
the number of human coronary endothelial muscarinic
receptors may have been insufficient to stimulate tPA
release. Further studies are needed to determine whether B2
receptor-specific stimulation and subsequent intracellular
signal transduction cause the release of tPA in human
coronary circulation.
Increased shear stress stimulates tPA release in cultured
human umbilical vein endothelial cells (7). In this study,
intracoronary infusion of papaverine, an endothelium-
independent vasodilator, did not increase tPA release in
human coronary circulation, even though it has a vasodila-
tory effect equipotent to that of BK. Therefore, flow-
induced coronary vasodilation may not be responsible for
the observed effect of BK on tPA release. We assumed that
BK stimulates tPA release through a direct action (possibly
by stimulating the B2-specific receptor) in human coronary
circulation.
In this study, ACE inhibitors had no effect on baseline
levels of tPA antigen or PAI-1 antigen in human coronary
circulation. Treatment with either captopril for four weeks
(20) or ramipril for two weeks (21) caused a significant
decrease in the level of tPA or PAI-1 antigen in patients
with myocardial infarction. The chronic effects of ACE
inhibitors on tPA and PAI-1 release should be examined
further.
PAI-1. Elevated levels of PAI-1 have been implicated in
the pathogenesis of myocardial infarction (22) and may
contribute to the risk of reinfarction in patients who have
suffered a previous myocardial infarction (23). It has been
shown that angiotensin II increased PAI-1 antigen levels in
humans (15). Many factors influence the production of
PAI-1 (e.g., glucose, insulin, estrogen and angiotensin II)
(24–26). Regulation of plasma levels of PAI-1 cannot be
explained solely by the renin-angiotensin system.
Intracoronary infusion of BK had no effects on PAI-1
levels at the Ao or CS in either group. Previous studies
demonstrated that infusion of BK or substance P, an
endothelium-dependent vasodilator, had no effects on cir-
culating PAI-1 levels but increased circulating tPA levels in
human forearm circulation (9,27). In this study, PAI-1
levels at the CS tended to decrease with increasing doses of
BK in both groups. On the other hand, infusion of
papaverine did not change PAI-1 levels in either the Ao or
CS. These results raise the possibility that the production
Figure 4. The effects of bradykinin (0.2, 0.6, 2.0 mg/min), acetylcholine (ACh) (30 mg/min) and papaverine (PA) (12 mg) on plasminogen activator
inhibitor (PAI-1) antigen in the aorta (Ao) and coronary sinus (CS) in the angiotensin-converting enzyme inhibitor group (open box) and the
nonangiotensin-converting enzyme inhibitor group (closed circle).
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and secretion of PAI-1 are modulated by the increased tPA
release in response to BK.
Study limitations. We did not examine whether the pres-
ence of coronary risk factors affect tPA release in response to
BK in the human coronary circulation. Further studies are
needed to determine whether there is a relationship between
the human coronary fibrinolytic response to BK and disor-
ders such as hypercholesterolemia, hypertension and insulin
resistance.
Blood flow in the CS is derived not only from LAD
coronary arteries but also from the left circumflex and right
coronary arteries. The amount of blood flow in LAD
coronary arteries is greater than that in the left circumflex or
right coronary arteries and is related to that in the left
circumflex and right coronary arteries (28). Therefore, we
defined net tPA release as the product of the CBF of LAD
coronary arteries and the difference in concentration be-
tween the Ao and the CS, although we did not have an
accurate net CBF.
Summary and clinical implications. We obtained two
novel observations in this study. First, intracoronary infu-
sion of BK stimulated tPA release in human coronary
circulation. Second, this effect of BK was augmented by the
administration of an ACE inhibitor. Therefore, ACE
inhibitors may have favorable effects on the coronary fi-
brinolytic balance in humans through the potentiation of
BK, resulting in a decrease in ischemic cardiovascular
events.
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